Epi Data Slicer
Research on the human microbiome is expanding beyond C. difficile, with microbiome-based therapies reaching the clinical trial phase of development for additional disease areas. Investments in this…
Research on the human microbiome is beginning to mature, with microbiome-based therapies reaching the clinical trial phase of development for many disease areas. There have been significant…
Market Outlook: Many cases of hospital-acquired infections and healthcare-associated illnesses are attributable to C. difficile infection (CDI). Although standard-of-care antibiotics are…
The past two decades have seen the arrival of revolutionary new biologic therapies for the treatment of numerous diseases, including inflammatory, hematologic, and malignant conditions. The…
What Clinical Improvements Will Differentiate Emerging Therapies in a Market with High Unmet Need and Rising Use of Microbiome-Based Treatments? Clostridium difficile infection (CDI) and…